

Bod Science completes recruitment of Phase IIb clinical trial of unique CBD product

- The Phase IIb clinical trial examines the efficacy of a unique CBD formulation on symptoms associated with insomnia in 198 participants over 8 weeks, undertaken by Australia's leading sleep research organisation, the Woolcock Institute of Medical Research
- The Last patient, First visit milestone sees the completion of recruitment for the clinical trial – meeting the Company's target of 198 patients recruited by the end of March 2023. The last patient is expected to complete the study by June 2023.
- Upon successful completion of the trial, Bod is hoping to have sufficient data to support a registration package, designed for Australia's Schedule 3 (pharmacist only) market

Sydney, Australia – 4 April 2023: Cannabis focused drug development and product innovation company Bod Science Limited ("Bod" or "the Company") (ASX: BOD) is pleased to advise the following update on their Phase IIb clinical trial for a new CBD product intended for Schedule 3 registration in the Australian market. The trial is being undertaken by Australia's leading sleep research organisation, the Woolcock Institute of Medical Research.

The trial assesses the efficacy of a uniquely developed Schedule 3 (Pharmacist Only) CBD formulation on symptoms associated with insomnia in 198 participants over an 8-week treatment period. Schedule 3 products can be sold to Australian consumers in pharmacy over the counter without a prescription. Bod's trial is a double blind, randomised and placebo-controlled investigation into the effect of administering 50mg or 100mg oral doses of a proprietary CBD product per day (refer to ASX announcement: 22 September 2021). The Phase IIb clinical trial completion is a significant step in the research and development for the new product and is expected to provide sufficient data for an application to register the low dose CBD product with the TGA. Bod's unique CBD formulation is presented in a soft gel capsule format and utilises a patent protected encapsulation technology that improves the bioavailability of the CBD extract.

In line with the anticipated timeframe, the Company has reached a major milestone to complete study recruitment, meeting the Company's target of 198 patients recruited by the end of March 2023. The 8-week treatment period is followed by a safety follow-up on week 12 for each patient.

Once the last patient completes the trial, Bod will move immediately to the data analysis stage. We look forward to reporting on the findings of the clinical trial and continuing our TGA submission preparations.

Management commentary:

CEO Ms Jo Patterson said: "We're thrilled to report that we've met our target of 198 patients recruited for our phase IIb trial by the end of March. With a number of remaining key milestones in near sight, we're anticipating the trial to provide suitable data for application to register and commercialise a new, low dose CBD product for the Australian schedule 3 market.

"Bod is reaching exciting milestones across both our two key clinical trials running in parallel, which provide Bod with the potential to access channels that significantly increase domestic sales, and optionality within the growing global CBD market."

This announcement has been approved by the Board of Bod Science Limited.

-ENDS-

About Bod Science:

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033